{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:57:20Z","timestamp":1791165440990,"version":"4.1.0"},"reference-count":197,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2023,2,11]]},"DOI":"10.1080\/14656566.2022.2161885","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T14:04:52Z","timestamp":1671717892000},"page":"331-346","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":22,"title":["Current and emerging drug treatment strategies to tackle invasive community-associated methicillin-resistant\n                    <i>Staphylococcus aureus<\/i>\n                    (MRSA) infection: what are the challenges?"],"prefix":"10.1080","volume":"24","author":[{"given":"Antonio","family":"Vena","sequence":"first","affiliation":[{"name":"San Martino Policlinico Hospital\u2014IRCCS for Oncology and Neurosciences","place":["Genoa, Italy"]},{"name":"University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Castaldo","sequence":"additional","affiliation":[{"name":"Azienda Sanitaria Universitaria Integrata di Udine","place":["Udine, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Magnasco","sequence":"additional","affiliation":[{"name":"San Martino Policlinico Hospital\u2014IRCCS for Oncology and Neurosciences","place":["Genoa, Italy"]},{"name":"University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bavastro","sequence":"additional","affiliation":[{"name":"San Martino Policlinico Hospital\u2014IRCCS for Oncology and Neurosciences","place":["Genoa, Italy"]},{"name":"University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Limongelli","sequence":"additional","affiliation":[{"name":"San Martino Policlinico Hospital\u2014IRCCS for Oncology and Neurosciences","place":["Genoa, Italy"]},{"name":"University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2385-1759","authenticated-orcid":false,"given":"Daniele Roberto","family":"Giacobbe","sequence":"additional","affiliation":[{"name":"San Martino Policlinico Hospital\u2014IRCCS for Oncology and Neurosciences","place":["Genoa, Italy"]},{"name":"University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[{"name":"San Martino Policlinico Hospital\u2014IRCCS for Oncology and Neurosciences","place":["Genoa, Italy"]},{"name":"University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh107"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70112-2"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/520195"},{"key":"e_1_3_5_6_1","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1086\/320184","article-title":"Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999","volume":"32","author":"Diekema DJ","unstructured":"Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001 May 15;32 Suppl 2:S114\u201332.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(09)70544-8"},{"issue":"1","key":"e_1_3_5_8_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/cid\/ciy399","article-title":"National costs associated with methicillin-susceptible and methicillin-resistant staphylococcus aureus hospitalizations in the United States, 2010-2014","volume":"68","author":"Klein EY","unstructured":"Klein EY, Jiang W, Mojica N, et al. National costs associated with methicillin-susceptible and methicillin-resistant staphylococcus aureus hospitalizations in the United States, 2010-2014. Clin Infect Dis. [2019 Jan 1];68(1):22\u201328.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2019.1677607"},{"issue":"33","key":"e_1_3_5_10_1","first-page":"1","article-title":"The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: a multicentre retrospective cohort study","volume":"21","author":"Stewardson AJ","unstructured":"Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: a multicentre retrospective cohort study. Euro Surveill. 2016 Aug 18;21(33):1\u201312.","journal-title":"Euro Surveill"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00020-18"},{"key":"e_1_3_5_12_1","first-page":"1532","volume-title":"Emerg infect dis","author":"Buck JM","year":"2005","unstructured":"Buck JM, Como-Sabetti K, Harriman KH, et al. Community-associated methicillin-resistant Staphylococcus aureus, Minnesota, 2000-2003. Emerg infect dis. 2005;11(10):1532\u20131538."},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005837"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1155\/2006\/402361"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-009-0721-9"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/milmed\/168.2.126"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1603\/0022-2585(2006)43[962:CHSANL]2.0.CO;2"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61999-1"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0710217105"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.22.2976"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.11.4289-4294.2002"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2008.02090.x"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-96-1-11"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00771-09"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2009.07.001"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2006.12.027"},{"issue":"2","key":"e_1_3_5_27_1","first-page":"S2-46","article-title":"Community-associated infections in children\u2013update on community-associated methicillin-resistant Staphylococcus aureus for the practitioner","volume":"17","author":"Immergluck LC","year":"2007","unstructured":"Immergluck LC. Community-associated infections in children\u2013update on community-associated methicillin-resistant Staphylococcus aureus for the practitioner. Ethn Dis. 2007;17(2):S2-46\u20139.","journal-title":"Ethn Dis"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-4-200802190-00204"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw240"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.10.1201"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1262-x"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01934.x"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm487"},{"key":"e_1_3_5_34_1","unstructured":"Surveillance of antimicrobial resistance in Europe. 2018:Available from 18 December 2022 at: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-resistance-europe-2018"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-009-0757-x"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp241"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.01.016"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1112.050241"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0706805"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix504"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ234"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1086\/511033"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1086\/587893"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2005.09.001"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07877-7"},{"issue":"6","key":"e_1_3_5_46_1","first-page":"e8867","article-title":"Understanding the Fight Against Resistance: Hospital-Acquired Methicillin-Resistant Staphylococcus Aureus vs. Community-Acquired Methicillin-Resistant Staphylococcus Aureus","volume":"12","author":"Tsouklidis N","year":"2020","unstructured":"Tsouklidis N, Kumar R, Heindl S, et al. Understanding the Fight Against Resistance: Hospital-Acquired Methicillin-Resistant Staphylococcus Aureus vs. Community-Acquired Methicillin-Resistant Staphylococcus Aureus Cureus. Cereus. 2020 Jun;12(6):e8867.","journal-title":"Cureus"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir034"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.05.006"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1086\/498901"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.1.108-118.2006"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1086\/426894"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.12.043"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-5-390"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1086\/377501"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.5.715"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.2.315"},{"issue":"4","key":"e_1_3_5_57_1","first-page":"584","article-title":"Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection","volume":"46","author":"Proctor RA","unstructured":"Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008 Feb 15;46(4):584\u2013593.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCC.0b013e32832f0a74"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1086\/529445"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.06.017"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.36.7.3273"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099044"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz460"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00341-09"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00582-2017"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12463"},{"issue":"2","key":"e_1_3_5_67_1","first-page":"ii45","article-title":"Safety and tolerability of linezolid","volume":"51","author":"French G","year":"2003","unstructured":"French G. Safety and tolerability of linezolid. J Antimicrob Chemother. 2003 May;51(2):ii45\u201353.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S33430"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010302"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2009.02701.x"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf192"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110152"},{"issue":"7","key":"e_1_3_5_73_1","first-page":"1148","article-title":"Vancomycin combined with clindamycin for the treatment of acute bacterial skin and skin-structure infections","volume":"61","author":"Wargo KA","unstructured":"Wargo KA, McCreary EK, English TM. Vancomycin combined with clindamycin for the treatment of acute bacterial skin and skin-structure infections. Clin Infect Dis. 2015 Oct 1;61(7):1148\u20131154.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01401-10"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01201-06"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.5.2996-3003.2001"},{"key":"e_1_3_5_77_1","unstructured":"Guidance on the diagnosis and management of PVL-associated Staphylococcus aureus infections (PVL-SA) in England.2nd Edition:Available from 22 December 2022 at: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/322857\/Guidance_on_the_diagnosis_and_management_of_PVL_associated_SA_infections_in_England_2_Ed.pdf"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.11.002"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.04.011"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200809040-00004"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01707-13"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02483-18"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02139-15"},{"key":"e_1_3_5_84_1","unstructured":"European Medicine Agency. Zinforo (ceftaroline fosamil). 2019: Available from 22 December 2022 at: https:\/\/www.ema.europa.eu\/documents\/overview\/zinforo-epar-medicine-overview_en.pdf."},{"key":"e_1_3_5_85_1","unstructured":"Food and Drug Administration. Teflaro\u2122 (ceftaroline fosamil). 2010: Available from 22 December 2022: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/200327s001lbl.pdf"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1086\/655827"},{"issue":"3","key":"e_1_3_5_87_1","first-page":"iii19","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File TM","year":"2011","unstructured":"File TM Jr., Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011 Apr;66(3):iii19\u201332.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_5_88_1","unstructured":"European Medicine Agency. Zinforo (ceftaroline fosamil). 2019: Available from 22 December 2022 https:\/\/www.ema.europa.eu\/documents\/overview\/zinforo-epar-medicine-overview_en.pdf."},{"key":"e_1_3_5_89_1","unstructured":"Administration FDA. Teflaro\u2122 (ceftaroline fosamil). Available from 22 December 2022 at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/200327s001lbl.pdf"},{"key":"e_1_3_5_90_1","unstructured":"EUCAST addendum to Breakpoint Table v 7.1. 2017: Available from 22 December 2022 at: http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/Addenda\/Addendum_2017-07-14.pdf"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx084"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-012-0449-9"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.11.005"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu219"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S56616"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1516749"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1086\/526527"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00551-07"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa974"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00886-09"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2019-0332"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00663-10"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.07.001"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2017.03.010"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0352-7"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02734-16"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1458"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.241"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70737-6"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00431-13"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S187499"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03688-14"},{"key":"e_1_3_5_113_1","unstructured":"Europenan medicine Agency. Sivextro tedizolid phosphate - Europa.eu. Available from 22 December 2022 at: www.ema.europa.eu\/documents\/overview\/sivextro-epar-medicine-overview_en.pdf"},{"key":"e_1_3_5_114_1","unstructured":"Food and Drug Administration . SIVEXTRO (tedizolid phosphate) 2014: Available from 22 December 2022 at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205435s000lbl.pdf"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab032"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00356-20"},{"issue":"1","key":"e_1_3_5_117_1","first-page":"1","article-title":"Long-term use of tedizolid in osteoarticular infections: benefits among oxazolidinone drugs","volume":"10","author":"Benavent E","unstructured":"Benavent E, Morata L, Escrihuela-Vidal F, et al. Long-term use of tedizolid in osteoarticular infections: benefits among oxazolidinone drugs. Antibiotics (Basel). 2021 Jan 8;10:(1):1\u201310.","journal-title":"Antibiotics (Basel)"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01383-07"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2012.11.036"},{"key":"e_1_3_5_120_1","unstructured":"ClinicalTrials GI: NCT00640926. Safety and efficacy study of oxazolidinone to treat pneumonia. 2008: Available from 22 December 2022 at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00640926."},{"key":"e_1_3_5_121_1","unstructured":"ClinicalTrials GI: NCT00646958. Safety and efficacy study of oxazolidinones to treat uncomplicated skin infections. 2008:Available from 22 December 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00646958."},{"key":"e_1_3_5_122_1","unstructured":"Clinicaltrials.gov.NCT00646958- Safety and efficacy study of oxazolidinones to treat uncomplicated skin infections. 2009."},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01526-13"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac073"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01576-0"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3260-3269.2003"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S142140"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.01.094"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz787"},{"issue":"1","key":"e_1_3_5_130_1","first-page":"ofz514","article-title":"A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial Pneumonia (DEFINE-CABP)","volume":"7","author":"Horcajada JP","year":"2020","unstructured":"Horcajada JP, Salata RA, Alvarez-Sala R, et al. A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial Pneumonia (DEFINE-CABP). Open Forum Infect Dis. 2020 Jan;7(1):ofz514.","journal-title":"Open Forum Infect Dis"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.10.009"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy165"},{"issue":"3","key":"e_1_3_5_133_1","first-page":"S223","article-title":"Analysis of pooled phase iii efficacy data for delafloxacin in acute bacterial skin and skin structure infections","volume":"68","author":"Giordano PA","unstructured":"Giordano PA, Pogue JM, Cammarata S. Analysis of pooled phase iii efficacy data for delafloxacin in acute bacterial skin and skin structure infections. Clin Infect Dis. 2019 Apr 8; 68(Suppl 3):S223\u2013S232.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_5_134_1","unstructured":"Food and Drug Administration. BAXDELA (delafloxacin) Label. 2017: Available from 22 December 2022 at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208610s000\/208611s000lbl.pdf"},{"key":"e_1_3_5_135_1","unstructured":"Food and Drug Administration. Prescribing information for baxdela available from 22 December 2022 at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208610s007 208611s006lbl.pdf"},{"key":"e_1_3_5_136_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06736-x"},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00078-09"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00295-10"},{"key":"e_1_3_5_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2015.09.005"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2017.07.011"},{"key":"e_1_3_5_141_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S248092"},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0270-0"},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.21307\/pjm-2019-007"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S90948"},{"key":"e_1_3_5_145_1","unstructured":"DONGWHA News.Dong wha obtains approval for zabolante from MFDS 2015 [cited 2020 Dec 22].Available at: https:\/\/www.dongwha.co.kr\/english\/customer\/dnews\/content.asp?t_idx=856"},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S105620"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05044-11"},{"key":"e_1_3_5_148_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt217"},{"key":"e_1_3_5_149_1","unstructured":"Clinicaltrials.gov.NCT03405064- comparative study of levonadifloxacin (IV and oral) with linezolid (IV and oral) in acute bacterial skin and skin structure infections (ABSSSI). 2020."},{"issue":"8","key":"e_1_3_5_150_1","first-page":"30","article-title":"Efficacy and safety of a novel broad-spectrum anti-mrsa agent levonadifloxacin compared with linezolid for acute bacterial skin and skin structure infections: a phase 3, openlabel, randomized study","volume":"68","author":"Bhatia A","year":"2020","unstructured":"Bhatia A, Mastim M, Shah M, et al. Efficacy and safety of a novel broad-spectrum anti-mrsa agent levonadifloxacin compared with linezolid for acute bacterial skin and skin structure infections: a phase 3, openlabel, randomized study. J Assoc Physicians India. 2020 Aug;68(8):30\u201336.","journal-title":"J Assoc Physicians India"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115195"},{"key":"e_1_3_5_152_1","volume-title":"Microbiologic analyses of target pathogens identified in the dalbavancin DISCOVER program ID week 3","author":"D M","year":"2018","unstructured":"D M. Microbiologic analyses of target pathogens identified in the dalbavancin DISCOVER program ID week 3. San Francisco California. 2018."},{"key":"e_1_3_5_153_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki008"},{"key":"e_1_3_5_154_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04550-14"},{"key":"e_1_3_5_155_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S86330"},{"key":"e_1_3_5_156_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1075508"},{"key":"e_1_3_5_157_1","doi-asserted-by":"publisher","DOI":"10.1086\/497271"},{"key":"e_1_3_5_158_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310480"},{"key":"e_1_3_5_159_1","unstructured":"Food F Administration D. Prescribing information for DALVANCE. 2014: Available from 22 December 2022 at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021883s000lbl.pdf"},{"issue":"10","key":"e_1_3_5_160_1","article-title":"Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care","volume":"9","author":"Ajaka L","unstructured":"Ajaka L, Heil E, Schmalzle S. Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care. Antibiotics (Basel). 2020 Oct 15;910","journal-title":"Antibiotics (Basel)"},{"key":"e_1_3_5_161_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.11.008"},{"key":"e_1_3_5_162_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2004.06.007"},{"key":"e_1_3_5_163_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-016-0103-4"},{"key":"e_1_3_5_164_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00766-08"},{"issue":"2","key":"e_1_3_5_165_1","first-page":"S223","article-title":"Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the solo ii noninferiority study","volume":"60","author":"Corey GR","unstructured":"Corey GR, Good S, Jiang H, et al. Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the solo ii noninferiority study. Clin Infect Dis. 2015 Jan 15 60(2):S223\u2013S232","journal-title":"Clin Infect Dis"},{"key":"e_1_3_5_166_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310422"},{"key":"e_1_3_5_167_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.07.019"},{"key":"e_1_3_5_168_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2015.1012498"},{"key":"e_1_3_5_169_1","doi-asserted-by":"publisher","DOI":"10.1086\/648438"},{"key":"e_1_3_5_170_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm211"},{"key":"e_1_3_5_171_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00100-07"},{"key":"e_1_3_5_172_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.4.458"},{"key":"e_1_3_5_173_1","doi-asserted-by":"publisher","DOI":"10.1086\/587896"},{"key":"e_1_3_5_174_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2008.05.012"},{"key":"e_1_3_5_175_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq031"},{"key":"e_1_3_5_176_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0505-8"},{"key":"e_1_3_5_177_1","unstructured":"Food and Drug Administration VIBATIV\u00ae (telavancin) package insert 2019: Available from 22 December 2022 at: www.vibativ.com\/public\/pdf\/PrescribingInformation.pdf."},{"key":"e_1_3_5_178_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-020-00191-x"},{"key":"e_1_3_5_179_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4093-1"},{"issue":"1","key":"e_1_3_5_180_1","first-page":"S6","article-title":"Microbiology and preclinical review of omadacycline","volume":"69","author":"Karlowsky JA","unstructured":"Karlowsky JA, Steenbergen J, Zhanel GG. Microbiology and preclinical review of omadacycline. Clin Infect Dis. 2019 Aug 1;69(Suppl 1):S6\u2013S15.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_5_181_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"e_1_3_5_182_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02411-16"},{"key":"e_1_3_5_183_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-018-1349-7"},{"key":"e_1_3_5_184_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01216-19"},{"key":"e_1_3_5_185_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30275-0"},{"key":"e_1_3_5_186_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800170"},{"key":"e_1_3_5_187_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800201"},{"key":"e_1_3_5_188_1","unstructured":"Food and Drug Administration . XERAVA (eravacycline) prescribing informations. Available from 22 December 2022 at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211109lbl.pdf"},{"key":"e_1_3_5_189_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02036-13"},{"key":"e_1_3_5_190_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.4237"},{"key":"e_1_3_5_191_1","unstructured":"ClinicalTrials GI: NCT01978938. Efficacy and safety study of eravacycline compared with levofloxacin in complicated urinary tract infections. 2013: Available from 22 December 2022 at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01978938."},{"key":"e_1_3_5_192_1","unstructured":"Food and Drug Administration. NUZYRA prescribing information. 2018: Available from 22 December 2022 at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209816_209817lbl.pdf."},{"key":"e_1_3_5_193_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-020-00732-z"},{"key":"e_1_3_5_194_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02161-18"},{"key":"e_1_3_5_195_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz090"},{"key":"e_1_3_5_196_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.15468"},{"key":"e_1_3_5_197_1","unstructured":"Food and drug administration . XENLETA prescribing information. 2019: Available from 22 December 2022 at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211672s000%2C211673s000lbl.pdf."},{"key":"e_1_3_5_198_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02106-12"},{"key":"e_1_3_5_199_1","volume-title":"Proceedings of the infectious disease (ID) week congress","author":"Thomson LH","unstructured":"Thomson LH, Cosgrove SE, Doernber SB, et al. Proceedings of the infectious disease (ID) week congress 2022 October 19-23 Washinghton DC: IASP PRESS."}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2022.2161885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:33:54Z","timestamp":1772728434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2022.2161885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":197,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2,11]]}},"alternative-id":["10.1080\/14656566.2022.2161885"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2022.2161885","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}